KLP Kapitalforvaltning AS Acquires New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

KLP Kapitalforvaltning AS bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 1,500 shares of the company’s stock, valued at approximately $33,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. American Century Companies Inc. grew its holdings in Dianthus Therapeutics by 3.8% during the 4th quarter. American Century Companies Inc. now owns 43,996 shares of the company’s stock valued at $959,000 after buying an additional 1,629 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $201,000. AlphaQuest LLC boosted its position in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after acquiring an additional 3,072 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Dianthus Therapeutics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock valued at $3,641,000 after purchasing an additional 1,092 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Dianthus Therapeutics by 3.8% in the fourth quarter. Rhumbline Advisers now owns 35,933 shares of the company’s stock worth $783,000 after acquiring an additional 1,316 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

DNTH has been the subject of several research analyst reports. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reissued a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Stock Up 12.9 %

DNTH stock opened at $17.61 on Friday. Dianthus Therapeutics, Inc. has a 52 week low of $13.37 and a 52 week high of $32.27. The stock has a market capitalization of $565.72 million, a PE ratio of -7.04 and a beta of 1.62. The firm has a 50 day moving average of $20.67 and a 200 day moving average of $23.38.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.